A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA)

Autor:	Jennifer K. Litton, Young-Hyuck Im, Lida Mina, Wolfgang Eiermann, Fran Visco, Nathalie Andrienne Lokker, Debra L. Lounsbury, Miguel Martin, Joanne L. Blum, Henri Roché, Charlie Zhang, Hope S. Rugo
Rok vydání:	2015
Předmět:	Cancer Research biology business.industry DNA repair Poly ADP ribose polymerase BRCA mutation Pharmacology medicine.disease Metastatic breast cancer chemistry.chemical_compound PARP1 Oncology chemistry PARP inhibitor biology.protein Cancer research Talazoparib Medicine business Polymerase
Zdroj:	Journal of Clinical Oncology. 33:TPS1107-TPS1107
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2015.33.15_suppl.tps1107
Popis:	TPS1107 Background: Poly-ADP-ribose polymerase (PARP) represents a family of enzymes of which at least two (PARP1 and PARP2) play important roles in DNA repair. PARP inhibition induces synthetic le...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::af1d2fd263cf370b00c10915c104aa2a https://doi.org/10.1200/jco.2015.33.15_suppl.tps1107 Zobrazit plný text záznamu